NCT02042378View on ClinicalTrials.gov

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Pancreatic CancerPancreatic Ductal Adenocarcinoma
Interventions
DRUG

Rucaparib

All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.

Trial Locations (8)

10012

New York University, New York

19104

University of Pennsylvania, Philadelphia

31096

Rambam Healthcare Campus, Haifa

55902

Mayo Clinic, Rochester

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

77030

MD Anderson Cancer Center, Houston

90048

Cedars Sinai Medical Center, Los Angeles

91120

Hadassah Hebrew University Hospital (Sharett Institute of Oncology), Jerusalem

All Listed Sponsors
lead

pharmaand GmbH

INDUSTRY

NCT02042378 - A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | Biotech Hunter | Biotech Hunter